Avanafil

SKU: orb1305659

Description

Avanafil is a potent and selective PDE5 inhibitor used in erectile dysfunction research. It is employed in both in vitro enzymatic assays and in vivo studies to investigate smooth muscle relaxation and hemodynamic effects in preclinical models.

Research Area

Immunology & Inflammation, Metabolism Research, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 330784-47-9
• MW: 483.95
• Purity: >99.99% (May vary between batches)
• Formula: C₂₃H₂₆ClN₇O₃
• SMILES: C(O)[C@H]1N(C=2N=C(NCC3=CC(Cl)=C(OC)C=C3)C(C(NCC=4N=CC=CN4)=O)=CN2)CCC1
• Target: NO Synthase,PDE,Endogenous Metabolite
• Solubility: H2O:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (6.82 mM);DMSO:90 mg/mL (185.97 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  PDE5:1 nM|PDE4:5700 nM|PDE1:53000 nM|PDE7:27000 nM|PDE6:630 nM|PDE2:51000 nM|PDE10:6200 nM
• In Vitro:
  In the corpus cavernosum of rats with Type 2 Diabetes Mellitus (T2DM), the injection of Avanafil (1 μM) has been demonstrated to enhance erectile function.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

NOS, inhibit, Nitric oxide synthases, NO Synthase, PDE5, osteoporosis, Inhibitor, Endogenous Metabolite, erectile dysfunction, Avanafil, bone density, dexamethasone, corpus cavernosum, phosphodiesterase, Phosphodiesterase (PDE), TA 1790, TA1790, TA-1790

Compound Identifiers

PubChem CID

9869929